Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MediCane's Medical Cannabis Oil for Agitation in Dementia
NCT06217146Phase 2Terminated
- Sponsor
- MediCane Health
- Start
- Oct 2022
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Dementia comparing MediCane's medical cannabis oil with Placebo (2 arms). Primary endpoints: Part 1 Safety (Adverse Events) at 22 weeks and Cohen-Mansfield Agitation Inventory at 12 weeks. Started Oct 2022; status: terminated.
02
Drugs
medical cannabis
03
Conditions
Dementia
Beyond the preview
Go deeper on NCT06217146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217146.